Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK1 | P06870 | 14/20 | 0.58 |
| ▸ | KLKB1 | P03952 | 13/20 | 0.53 |
| ▸ | DNM1L | O00429 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12584702 | 0.92 | KLK1 (0.57) | KLK1KLKB1 | |
| SCHEMBL988887 | 0.88 | KLK1 (0.55) | KLK1KLKB1DNM1LPTGER4PTGDR | |
| SCHEMBL12584717 | 0.85 | KLK1 (0.47) | KLK1KLKB1DNM1LPTGER4PTGDR | |
| SCHEMBL12585796 | 0.85 | PTGER4 (0.49) | PTGER4PTGDR | |
| SCHEMBL12585656 | 0.83 | PTGER4 (0.50) | PTGER4PTGDR | |
| SCHEMBL987780 | 0.83 | PTGER4 (0.50) | PTGER4PTGDR | |
| SCHEMBL12585316 | 0.82 | PTGER4 (0.59) | PTGER4PTGDR | |
| SCHEMBL985984 | 0.81 | KLK1 (0.46) | KLK1KLKB1 | |
| SCHEMBL27855513 | 0.81 | KLK1 (0.46) | KLK1KLKB1 | |
| SCHEMBL12584734 | 0.80 | KLK1 (0.55) | KLK1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598355-B2 | Amide compound | ASTELLAS PHARMA INC. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2565191-A1 | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy | Astellas Pharma Inc. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-20110144153-A1 | AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-16 | — | — | US | disclosed |
| CN-102026961-A | Amide compound | ASTELLAS PHARMA INC | 2011-04-20 | — | — | CN | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| EP-2277858-A1 | AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009139373-A1 | AMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144153-A1 | AMIDE COMPOUND | PTGER4, PTGER1, PTGER2 | KLK1 1672/4885KLKB1 2890/4885DNM1L 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.